<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The primary pathology in many cases of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) remains unknown </plain></SENT>
<SENT sid="1" pm="."><plain>In some cases, two or more affected members have been identified in the same family </plain></SENT>
<SENT sid="2" pm="."><plain>To date, mutations in two genes have been directly implicated: the hematopoietic transcription factors RUNX1 (<z:mp ids='MP_0001265'>runt</z:mp>-related transcription factor 1) and CEBPA (CCATT-box enhancer binding protein alpha) </plain></SENT>
<SENT sid="3" pm="."><plain>However, there are also other familial cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> where the genetic basis remains unknown </plain></SENT>
<SENT sid="4" pm="."><plain>Both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and to a lesser extent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, have been observed in cases of the <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> syndrome <z:mp ids='MP_0009563'>dyskeratosis</z:mp> congenita, in which telomerase mutations have been identified </plain></SENT>
<SENT sid="5" pm="."><plain>Recently, an increased incidence of telomerase reverse transcriptase mutations has been reported in a series of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>We have now identified novel mutations in the telomerase <z:chebi fb="40" ids="33697">RNA</z:chebi> (TERC) or telomerase reverse transcriptase component (TERT) within 4 of 20 families presenting with familial <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Functional analysis has demonstrated that <z:hpo ids='HP_0000001'>all</z:hpo> mutations adversely impact on telomerase activity in vitro, and affected individuals have short telomeres </plain></SENT>
<SENT sid="8" pm="."><plain>These families, in conjunction with a review of previously published cases, help to further define the pathological role of telomerase mutations in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and have implications for the biology, treatment and screening regimen of de novo cases </plain></SENT>
</text></document>